This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Cancer Research Technology Limited. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Birgit Wilding: Innovator in Cancer Research
Introduction
Birgit Wilding is a notable inventor based in Sutton Coldfield, GB. She has made significant contributions to the field of cancer research through her innovative work on quinoline derivatives. Her research focuses on developing therapeutic agents aimed at treating and preventing proliferative diseases, particularly cancer.
Latest Patents
Birgit Wilding holds a patent for "Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity." This invention relates to compounds that inhibit the heat shock factor 1 pathway, which is crucial in the development of various diseases. The compounds are designed to serve as therapeutic agents, providing new avenues for cancer treatment.
Career Highlights
Wilding's career is marked by her dedication to advancing cancer research. She has been instrumental in exploring the potential of quinoline derivatives, contributing to the understanding of their role in inhibiting disease pathways. Her work has implications for the development of new cancer therapies.
Collaborations
Birgit has collaborated with notable colleagues, including Nicola Chessum and Elisa Pasqua. These partnerships have enhanced her research efforts and contributed to the advancement of innovative solutions in cancer treatment.
Conclusion
Birgit Wilding's contributions to cancer research through her patented inventions highlight her role as a leading innovator in the field. Her work continues to pave the way for new therapeutic approaches to combat cancer.